EventsMOL2NET'23, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 9th ed.
Event submissions
Published
This submission belongs to the session 02. CHEMBIO.MOL-09: Org. Chem., Med. Chem., Mol. Biol., & Pharm. Industry Congress, Paris, France-Fargo, USA, 2023. of the event MOL2NET'23, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 9th ed.
Published date
24 Dec, 2023
Academic Editor
author-avatarHumbert G. Díaz
Citation
Khyati Bhagdev, Chintan Jamanbhai Tank, Development of UV Spectrophotometric Methods and Validation for Estimation of Dapagliflozin in Bulk and Tablet Dosage Form by Absorbance Maxima and Area Under the Curve Method, in Proceedings of MOL2NET'23, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 9th ed., 25 December–31 December 2023, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Development of UV Spectrophotometric Methods and Validation for Estimation of Dapagliflozin in Bulk and Tablet Dosage Form by Absorbance Maxima and Area Under the Curve Method

Khyati Bhagdev 1
Chintan Jamanbhai Tank 1
1. School of Pharmacy, Dr. Subhash University, Junagadh, Gujarat, India, India
Abstract

UV spectrophotometric method was developed for the determination of dapagliflozin in pure form and in tablets. The method was developed using methanol and water as diluents. The results were achieved by using two methods: absorbance maxima and area under the curve method. All the parameters were chosen according to ICH [Q2(R1)] guideline and validated statistically using RSD and %RSD. The results of validation parameters were within the range. The developed method is accurate and precise.

Keywords
Dapagliflozin
antidiabetic agent
UV spectrophotometry
validation parameters
Manuscript
Manuscript in modified format.pdf
The investigation of crucial tests for medium voltage vacuum circuit breaker
Poinsettifolin A: virtual screening of flavonoids through molecular docking, dynamics and MM/PBSA studies identify compound as potential NLRP3 inflammasome inhibitor